Regulatory T cells as central regulators of both autoimmunity and B cell malignancy in New Zealand Black mice

Journal of Autoimmunity

Volumn 32, Issue 1, 2009, Pages 14-23

  Scaglione, Brian J ^a   Salerno, Erica ^a   Gala, Kinisha ^a   Pan, Manjing ^b   Langer, Jerome A ^b   Mostowski, Howard S ^c   Bauer, Steven ^c   Marti, Gerald ^c   Li, Yu ^d   Tsiagbe, Vincent K ^a,d   Raveche, Elizabeth S ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^d RUTGERS SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

Autoimmunity; Regulatory T cells; Tumor immunity

Indexed keywords

ALPHA INTERFERON; CD5 ANTIGEN; IMMUNOGLOBULIN M; TRANSCRIPTION FACTOR FOXP3;

ANIMAL EXPERIMENT; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CELL DIFFERENTIATION; CONTROL GROUP; EX VIVO STUDY; EXPERIMENTAL MOUSE; FEMALE; FLOW CYTOMETRY; IN VIVO STUDY; MOUSE; NEW ZEALAND; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN CELL;

AGE FACTORS; ANIMALS; ANTIBODIES; ANTIBODIES, ANTINUCLEAR; ASCITIC FLUID; AUTOIMMUNE DISEASES; AUTOIMMUNITY; B-LYMPHOCYTES; ERYTHROCYTES; FORKHEAD TRANSCRIPTION FACTORS; IMMUNE TOLERANCE; INTERFERON-ALPHA; INTERFERONS; INTERLEUKIN-10; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LEUKEMIA, B-CELL; LYMPH NODES; MICE; MICE, INBRED C57BL; MICE, INBRED NZB; POLY I-C; SPLEEN; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 58849153134     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2008.10.001     Document Type: Article

References (68)

1. Piccirillo C.A., and Shevach E.M. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 167 (2001) 1137-1140
2. Shevach E.M. Regulatory/suppressor T cells in health and disease. Arthritis Rheum 50 (2004) 2721-2724
3. Jiang H., and Chess L. Regulation of immune responses by T cells. N Engl J Med 354 (2006) 1166-1176
4. Curiel T.J. Tregs and rethinking cancer immunotherapy. J Clin Invest 117 (2007) 1167-1174
5. Itoh M., Takahashi T., Sakaguchi N., Kuniyasu Y., Shimizu J., Otsuka F., et al. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 162 (1999) 5317-5326
6. Choileain N.N., and Redmond H.P. Regulatory T-cells and autoimmunity. J Surg Res 130 (2006) 124-135
7. Longhi M.S., Hussain M.J., Mitry R.R., Arora S.K., Mieli-Vergani G., Vergani D., et al. Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol 176 (2006) 4484-4491
8. Takahashi T., and Sakaguchi S. Naturally arising CD25+CD4+ regulatory T cells in maintaining immunologic self-tolerance and preventing autoimmune disease. Curr Mol Med 3 (2003) 693-706
9. Ono M., Shimizu J., Miyachi Y., and Sakaguchi S. Control of autoimmune myocarditis and multiorgan inflammation by glucocorticoid-induced TNF receptor family-related protein (high), Foxp3-expressing CD25+ and CD25- regulatory T cells. J Immunol 176 (2006) 4748-4756
10. Ghiringhelli F., Menard C., Terme M., Flament C., Taieb J., Chaput N., et al. CD4+ CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 202 (2005) 1075-1085
11. Marshall N.A., Christie L.E., Munro L.R., Culligan D.J., Johnston P.W., Barker R.N., et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 103 (2004) 1755-1762
12. Giannopoulos K., Schmitt M., Wlasiuk P., Chen J., Bojarska-Junak A., Kowal M., et al. The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide. Leukemia 22 (2008) 222-224
13. Beyer M., Kochanek M., Darabi K., Popov A., Jensen M., Endl E., et al. Reduced frequencies and suppressive function of CD4+ CD25 high regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 106 (2005) 2018-2025
14. Hahn B.H., Ebling F., Singh R.R., Singh R.P., Karpouzas G., and La Cava A. Cellular and molecular mechanisms of regulation of autoantibody production in lupus. Ann N Y Acad Sci 1051 (2005) 433-441
15. Horwitz D.A., Zheng S.G., Gray J.D., Wang J.H., Ohtsuka K., and Yamagiwa S. Regulatory T cells generated ex vivo as an approach for the therapy of autoimmune disease. Semin Immunol 16 (2004) 135-143
16. Crispin J.C., Martinez A., and Alcocer-Varela J. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 21 (2003) 273-276
17. La Cava A. T-regulatory cells in systemic lupus erythematosus. Lupus 17 (2008) 421-425
18. Liu M.F., Wang C.R., Fung L.L., and Wu C.R. Decreased CD4+ CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus. Scand J Immunol 59 (2004) 198-202
19. Valencia X., Yarboro C., Illei G., and Lipsky P.E. Deficient CD4+ CD25 high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 178 (2007) 2579-2588
20. Wu H.Y., and Staines N.A. A deficiency of CD4+CD25+ T cells permits the development of spontaneous lupus-like disease in mice, and can be reversed by induction of mucosal tolerance to histone peptide autoantigen. Lupus 13 (2004) 192-200
21. Hsu W.T., Suen J.L., and Chiang B.L. The role of CD4CD25 T cells in autoantibody production in murine lupus. Clin Exp Immunol 145 (2006) 513-519
22. Theofilopoulos A.N., and Dixon F.J. Murine models of systemic lupus erythematosus. Adv Immunol 37 (1985) 269-390
23. Scalapino K.J., Tang Q., Bluestone J.A., Bonyhadi M.L., and Daikh D.I. Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunol 177 (2006) 1451-1459
24. Raveche E.S., and Steinberg A.D. Lymphocytes and lymphocyte functions in systemic lupus erythematosus. Semin Hematol 16 (1979) 344-370
25. Theofilopoulos A.N. Genetics of systemic autoimmunity. J Autoimmun 9 (1996) 207-210
26. Giles B.M., Tchepeleva S.N., Kachinski J.J., Ruff K., Croker B.P., Morel L., et al. Augmentation of NZB autoimmune phenotypes by the Sle1c murine lupus susceptibility interval. J Immunol 178 (2007) 4667-4675
27. Phillips J.A., Mehta K., Fernandez C., and Raveche E.S. The NZB mouse as a model for chronic lymphocytic leukemia. Cancer Res 52 (1992) 437-443
28. Hall A.M., Vickers M.A., McLeod E., and Barker R.N. Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells. Blood 105 (2005) 2007-2015
29. Hall A.M., Ward F.J., Shen C.R., Rowe C., Bowie L., Devine A., et al. Deletion of the dominant autoantigen in NZB mice with autoimmune hemolytic anemia: effects on autoantibody and T-helper responses. Blood 110 (2007) 4511-4517
30. Raveche E.S., Tjio J.H., and Steinberg A.D. Genetic studies in NZB mice. II. Hyperdiploidy in the spleen of NZB mice and their hybrids. Cytogenet Cell Genet 23 (1979) 182-193
31. Raveche E.S., and Tjio J.H. Hyperdiploid-CD5-positive B cells in mouse. Int J Hematol 54 (1991) 25-35
32. Schuster H., Martin T., Marcellin L., Garaud J.C., Pasquali J.L., and Korganow A.S. Expansion of marginal zone B cells is not sufficient for the development of renal disease in NZB×NZW F1 mice. Lupus 11 (2002) 277-286
33. Heremans H., Billiau A., Colombatti A., Hilgers J., and de Somer P. Interferon treatment of NZB mice: accelerated progression of autoimmune disease. Infect Immun 21 (1978) 925-930
34. Raveche E., Fernandes H., Ong H., and Peng B. Regulatory role of T cells in a murine model of lymphoproliferative disease. Cell Immunol 187 (1998) 67-75
35. Coughlin C.M., Salhany K.E., Gee M.S., LaTemple D.C., Kotenko S., Ma X., et al. Tumor cell responses to IFN gamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9 (1998) 25-34
36. Lasfar A., Lewis-Antes A., Smirnov S.V., Anantha S., Abushahba W., Tian B., et al. Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res 66 (2006) 4468-4477
37. Rehberg E., Kelder B., Hoal E.G., and Pestka S. Specific molecular activities of recombinant and hybrid leukocyte interferons. J Biol Chem 257 (1982) 11497-11502
38. Streuli M., Hall A., Boll W., Stewart II W.E., Nagata S., and Weissmann C. Target cell specificity of two species of human interferon-alpha produced in Escherichia coli and of hybrid molecules derived from them. Proc Natl Acad Sci U S A 78 (1981) 2848-2852
39. Weck P.K., Apperson S., Stebbing N., Gray P.W., Leung D., Shepard H.M., et al. Antiviral activities of hybrids of two major human leukocyte interferons. Nucleic Acids Res 9 (1981) 6153-6166
40. Familletti P.C., Rubinstein S., and Pestka S. A convenient and rapid cytopathic effect inhibition assay for interferon. Meth Enzymol 78 (1981) 387-394
41. Sato S., Ono N., Steeber D.A., Pisetsky D.S., and Tedder T.F. CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J Immunol 157 (1996) 4371-4378
42. Ramachandra S., Metcalf R.A., Fredrickson T., Marti G.E., and Raveche E. Requirement for increased IL-10 in the development of B-1 lymphoproliferative disease in a murine model of CLL. J Clin Invest 98 (1996) 1788-1793
43. Czarneski J., Lin Y.C., Chong S., McCarthy B., Fernandes H., Parker G., et al. Studies in NZB IL-10 knockout mice of the requirement of IL-10 for progression of B-cell lymphoma. Leukemia 18 (2004) 597-606
44. Levings M.K., and Roncarolo M.G. T-regulatory 1 cells: a novel subset of CD4 T cells with immunoregulatory properties. J Allergy Clin Immunol 106 (2000) S109-S112
45. Taganov K.D., Boldin M.P., and Baltimore D. MicroRNAs and immunity: tiny players in a big field. Immunity 26 (2007) 133-137
46. Steinberg A.D., Baron S., and Talal N. The pathogenesis of autoimmunity in New Zealand mice, I. Induction of antinucleic acid antibodies by polyinosinic-polycytidylic acid. Proc Natl Acad Sci U S A 63 (1969) 1102-1107
47. Carpenter D.F., Steinberg A.D., Schur P.H., and Talal N. The pathogenesis of autoimmunity in New Zealand mice. II. Acceleration of glomerulonephritis by polyinosinic-polycytidylic acid. Lab Invest 23 (1970) 628-634
48. Santiago-Raber M.L., Baccala R., Haraldsson K.M., Choubey D., Stewart T.A., Kono D.H., et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 197 (2003) 777-788
49. Ytterberg S.R., and Schnitzer T.J. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 25 (1982) 401-406
50. Hooks J.J., Moutsopoulos H.M., Geis S.A., Stahl N.I., Decker J.L., and Notkins A.L. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 301 (1979) 5-8
51. Pellicano R., Smedile A., Peyre S., Astegiano M., Saracco G., Bonardi R., et al. Autoimmune manifestations during interferon therapy in patients with chronic hepatitis C: the hepatologistis view. Minerva Gastroenterol Dietol 51 (2005) 55-61
52. Gota C., and Calabrese L. Induction of clinical autoimmune disease by therapeutic interferon-alpha. Autoimmunity 36 (2003) 511-518
53. Fleischmann M., Celerier P., Bernard P., Litoux P., and Dreno B. Long-term interferon-alpha therapy induces autoantibodies against epidermis. Dermatology 192 (1996) 50-55
54. Fragale A., Gabriele L., Stellacci E., Borghi P., Perrotti E., Ilari R., et al. IFN regulatory factor-1 negatively regulates CD4+CD25+ regulatory T cell differentiation by repressing Foxp3 expression. J Immunol 181 (2008) 1673-1682
55. Borchers A., Ansari A.A., Hsu T., Kono D.H., and Gershwin M.E. The pathogenesis of autoimmunity in New Zealand mice. Semin Arthritis Rheum 29 (2000) 385-399
56. Laronne-Bar-On A., Zipori D., and Haran-Ghera N. Increased regulatory versus effector T cell development is associated with thymus atrophy in mouse models of multiple myeloma. J Immunol 181 (2008) 3714-3724
57. Field E.H., Kulhankova K., and Nasr M.E. Natural Tregs, CD4+CD25+ inhibitory hybridomas, and their cell contact dependent suppression. Immunol Res 39 (2007) 62-78
58. von Herrath M.G., and Harrison L.C. Antigen-induced regulatory T cells in autoimmunity. Nat Rev Immunol 3 (2003) 223-232
59. Fayad L., Keating M., Reuben J., O'Brien S., Lee B., Lerner S., et al. IL-6 and IL-10 levels in CLL: correlation with phenotypic characteristic and outcome. Blood 97 (2001) 256-263
60. Gonzalez H., Leblond V., Azar N., Sutton L., Gabarre J., Binet J.L., et al. Severe autoimmune hemolytic anemia in eight patients treated with fludarabine. Hematol Cell Ther 40 (1998) 113-118
61. Rousset F., Garcia E., Defrance T., Peronne C., Vezzio N., Hsu D.H., et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A 89 (1992) 1890-1893
62. Cuda C.M., Wan S., Sobel E.S., Croker B.P., and Morel L. Murine lupus susceptibility locus Sle1a controls regulatory T cell number and function through multiple mechanisms. J Immunol 179 (2007) 7439-7447
63. Kim V.N. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 6 (2005) 376-385
64. Cobb B.S., Hertweck A., Smith J., O'Connor E., Graf D., Cook T., et al. A role for dicer in immune regulation. J Exp Med 203 (2006) 2519-2527
65. Scaglione B.J., Salerno E., Balan M., Coffman F., Landgraf P., Abbasi F., et al. Murine models of chronic lymphocytic leukaemia: role of microRNA-16 in the New Zealand Black mouse model. Br J Haematol 139 (2007) 645-657
66. Calin G.A., Dumitru C.D., Shimizu M., Bichi R., Zupo S., Noch E., et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 99 (2002) 15524-15529
67. Raveche E.S., Salerno E., Scaglione B.J., Manohar V., Abbasi F., Lin Y.C., et al. Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice. Blood 109 (2007) 5079-5086
68. Calin G.A., Ferracin M., Cimmino A., Di Leva G., Shimizu M., Wojcik S.E., et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353 (2005) 1793-1801